NK Cell Therapy in Osaka: Records and Follow-Up Abroad

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

If you are considering NK cell therapy in Osaka while living abroad, one practical question tends to come up early: what happens after you fly home? Cancer care rarely sits in one place. Your oncologist, your hospital records and your follow-up appointments are probably in another country, and any treatment you receive in Japan needs to fit into that picture. This article explains what international patients may want to ask about records, communication and continuity of care before and after NK cell therapy at Grand Green Osaka Umekita Clinic in Umeda, Osaka.

In short, NK cell therapy is a cancer immune cell therapy that uses your own cells, and it is described as something that can be used alongside standard treatment rather than instead of it. Whether it suits you, and how it is coordinated with your current care, is a decision for a doctor to make after a consultation. Nothing here is a promise of any outcome.

Why continuity of care matters for international patients

NK cell therapy is a self-pay (non-insured) treatment in Japan. It takes place in a different country from where many patients receive their main cancer care. That distance can create gaps: your home oncologist may not know what was given, and the clinic in Osaka may not know what you are currently taking or what your latest scans showed.

Closing those gaps is mostly a matter of information. Doctors on both sides make better decisions when they can see the same facts, such as your diagnosis, your treatment history, your current medications and your recent test results. Asking early how the clinic handles this is a sensible part of preparing for a consultation.

What NK cell therapy involves, and why it affects your records

NK (natural killer) cells are immune cells that circulate in the blood and are thought to help detect and attack abnormal cells. In this therapy, NK cells obtained from a standard blood draw are activated and expanded at a specialized facility, then returned to your body by intravenous infusion. Because your own cells are used, it is called an autologous therapy.

From a records point of view, this means there are several documented steps: the blood collection, the cell preparation and the infusions themselves. Each of these generates information that your home doctor may find useful, particularly if you later develop a fever, fatigue or another change in how you feel. Temporary fever or fatigue has been described as a possible reaction, so it helps if a doctor at home knows what treatment you received and when.

Documents and information worth gathering before you travel

Preparing in advance usually makes a first consultation more productive. Many patients find it helpful to collect the following, in English where possible, and to ask the clinic which formats it can accept:

• A recent summary from your treating doctor, including your diagnosis and treatment history
• Recent imaging reports and blood test results
• A current list of medications, including chemotherapy, targeted drugs and supplements
• Details of any planned surgery, chemotherapy or radiation therapy
• Any known allergies or past reactions to infusions

If you have documents in another language, ask whether translated versions are needed. It is also reasonable to ask how the clinic stores and protects the personal data you share, and whether you can request a copy of your own records afterward.

Coordinating with your oncologist back home

Standard cancer treatment such as surgery, chemotherapy and radiation therapy is not replaced by NK cell therapy. The clinic states that the therapy does not interfere with these treatments and that it can coordinate with the medical institution providing your standard care. What that coordination looks like in practice can vary, so ask directly.

Useful questions include whether the clinic can send a treatment summary to your home doctor, whether it can speak with your doctor if your doctor agrees, and how the timing of any infusion might relate to your chemotherapy or radiation schedule. Your home oncologist may also have views about timing or monitoring. It can help to tell that doctor about your plans before you travel, so that no one is surprised, and so that your overall plan stays consistent.

Be cautious about any suggestion that you should pause or change your standard treatment. Decisions like that belong with the physicians responsible for your cancer care, and a reputable clinic should be comfortable with you consulting them.

Language support, follow-up and planning the practicalities

Language can affect how well you understand risks, consent and aftercare instructions. Grand Green Osaka Umekita Clinic offers information pages for international patients in several languages, and you can ask which languages are available during an actual consultation, including whether interpretation is provided and whether written instructions can be given to you in a language you read comfortably.

Follow-up deserves the same attention. Ask what to do if you feel unwell after returning home, who you should contact, and whether online or telephone follow-up is possible. Also ask how the schedule of visits is arranged, because travel time, work and family commitments all affect what is realistic for you.

Because Japan regulates cell therapies like this one under the Act on the Safety of Regenerative Medicine, treatment is provided under a plan that has been submitted to and accepted by the authorities. It is reasonable to ask the clinic to explain how this applies to your case. Fees, risks, side effects and whether you are a suitable candidate are all matters to confirm with a doctor during consultation, because they depend on your individual condition.

Questions to take with you

• What information from my home hospital do you need before the consultation?
• Can you share a treatment summary with my oncologist, and in what language?
• How might the timing relate to my current chemotherapy or radiation schedule?
• Who do I contact if I have symptoms after I return home?
• What are the costs, risks and limits of this therapy for someone in my situation?

These questions are a starting point, not a checklist that guarantees anything. Their purpose is to help you arrive at your consultation informed and to keep both your Osaka doctor and your home doctor working from the same information.

Summary

For international patients, thinking about records and follow-up is as important as thinking about the treatment itself. Gather your medical history, talk with your oncologist before you travel, and ask the Osaka clinic how it communicates with home doctors and supports patients in your language. NK cell therapy is a self-pay treatment, and its suitability, cost and risks must be confirmed with a doctor after an examination. If you would like to learn more, the NK cell therapy information page of Grand Green Osaka Umekita Clinic is a reasonable place to begin.

• Gather your recordsDiagnosis, scans, medications
• Talk to your oncologistBefore you travel
• Ask about language supportInterpretation and written guidance
• Plan after-return follow-upWho to contact if unwell

This figure is a conceptual diagram that summarizes the article

References

• PMC: Chronic exercise training intensity, immune cells, and cancer outcomes: a scoping review. (2026)
• PMC: Targeting innate and adaptive immunity to suppress lung cancer metastasis. (2025)
• PMC: A precision immuno-oncology turn? Hybridizing cancer genomics and immunotherapy through neoantigens-based adoptive cell therapies. (2025)
• PMC: Auditory stimulation of opera music induced prolongation of murine cardiac allograft survival and maintained generation of regulatory CD4+CD25+ cells. (2012)
• MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.